TVRD — Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 12
- Website: https://tvarditherapeutics.com
Latest SEC filings for TVRD
- 8-K — 2026-08-14
- 10-Q — 2026-08-14
- 8-K — 2026-07-30
- 8-K — 2026-07-17
- 424B5 — 2026-07-17
- 424B5 — 2026-07-17
- 8-K — 2026-07-07
- 8-K — 2026-06-11
- EFFECT — 2026-05-14
- EFFECT — 2026-05-13
Latest TVRD news
- — Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference (GlobeNewswire Inc.)
- — TVA First U.S. Utility to Receive Construction Permit for BWRX-300 Advanced Nuclear Reactor (prnewswire_all)
Educational tool only — not investment advice.